Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Genetic Testing

BCR-ABL1 Quantitative p210p190p230

The BCR-ABL1 Quantitative p210p190p230 test measures the levels of specific genetic markers associated with Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). It helps in diagnosing and monitoring these conditions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Peripheral blood or bone marrow sample.
Results
Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. Specific preparation instructions may be provided by your doctor.
Test priceKSh 18,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the BCR-ABL1 Quantitative p210p190p230 test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of suspected Chronic Myeloid Leukemia (CML).
  • ✓Diagnosis of suspected Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
  • ✓Monitoring treatment response in CML and Ph+ ALL patients.
  • ✓Assessing minimal residual disease (MRD) after therapy.
  • ✓Evaluating disease progression or relapse.
02

In plain language

What this test helps you understand

This test is used for the diagnosis, prognosis, and monitoring of treatment response in patients with suspected or confirmed Chronic Myeloid Leukemia (CML) or Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). It helps quantify the level of the BCR-ABL1 fusion gene, providing critical information for managing these conditions.
The BCR-ABL1 Quantitative p210p190p230 test is a specialized genetic test used to detect and monitor certain types of leukemia, particularly Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). This test quantifies the amount of BCR-ABL1 fusion gene transcripts in a blood or bone marrow sample. These transcripts are produced by an abnormal fusion of chromosomes 9 and 22, known as the Philadelphia chromosome, which is characteristic of these leukemias. Measuring the quantity of these transcripts is crucial for diagnosing the disease, assessing its progression, and monitoring the effectiveness of treatment. The test helps healthcare providers understand how well a patient is responding to therapy and make informed decisions about treatment adjustments. It is often used to track minimal residual disease (MRD) after treatment, which can indicate the risk of relapse.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. Specific preparation instructions may be provided by your doctor.
SamplePeripheral blood or bone marrow sample.
MethodologyQuantitative Polymerase Chain Reaction (qPCR) or similar molecular techniques.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific BCR-ABL1 fusion transcripts (p210, p190, p230). Results may be affected by sample quality or interfering substances. Interpretation requires clinical correlation.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The BCR-ABL1 fusion gene is an abnormal gene created when parts of chromosome 9 and chromosome 22 break and join together. This fusion is characteristic of certain types of leukemia, like CML and Ph+ ALL.
Quantifying the BCR-ABL1 transcripts helps doctors understand the amount of leukemia cells present, monitor how well treatment is working, and detect potential relapse earlier.
A higher level generally indicates a larger number of leukemia cells or less effective treatment. Your doctor will interpret the results in the context of your overall health.
This specific test is primarily used for CML and Ph+ ALL. Other genetic tests are used for different conditions.
The sample is typically collected as a blood draw (peripheral blood) or a bone marrow aspiration. Your doctor will advise on the appropriate collection method.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Beta CTx Beta Crosslaps Collagen Type 1 C-Telopeptide Test

The Beta CTx test measures bone resorption markers to help assess bone health and osteoporosis risk.

Learn more →

Bcell Rearrangement Detection Test

The Bcell Rearrangement Detection Test helps diagnose leukemia by identifying genetic changes in B cells. It's a key tool for hematologists and oncologists.

Learn more →

Dpd Gene Mutations 5Fu Toxicity Detection Test

This genetic test identifies mutations in the DPD gene, helping predict the risk of severe side effects from the chemotherapy drug 5-fluorouracil (5FU).

Learn more →

Ganciclovir Resistance Detection Test

This test checks for genetic changes in the cytomegalovirus (CMV) that may make it resistant to the antiviral medication Ganciclovir. It helps guide treatment decisions, especially for patients with weakened immune systems.

Learn more →
Chat on WhatsApp